UY Scuti Acquisition, a blank check company targeting middle-market growth businesses, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering.
The New York, NY-based company plans to raise $50 million by offering 5 million units at $10. Each unit consists of one share of common stock and one right to receive one-fifth of a share upon the completion of an initial business combination.
UY Scuti Acquisition is led by CEO and Director Jialuan Ma, who most recently served as the Financial Director of Roche Pharma China. The SPAC plans to target middle-market growth businesses with total enterprise values between $200 million and $400 million.
UY Scuti Acquisition was founded in 2024 and plans to list on the Nasdaq under the symbol UYSCU. Maxim Group LLC is the sole bookrunner on the deal.
